Condition: Schizophrenia · Alzheimer's Disease Psychosis · Sponsor: Luye Pharma Group Ltd.
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
This description comes directly from the study's public registry record.
Yufeng Wang · 86+18665029373 · wangyufeng@luye.com
Always discuss trial participation with your own doctor first.
| Beijing AnDing Hospital Capital Medical University | Beijing, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07230652